osimertinib
astrazeneca
['lcsm,(-blcsm)', 'osimertinib']
phase ii trial of neoadjuvant osimertinib by . satisfactory r0 resection rate (89%) with manageable toxicities. still, more to do concerning efficacy (15% mpr). an impressive, exemplary translational research as a treasure of neoadjuvant strategy. #asco23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC